Watch Stryker’s Q2 2026 Earnings: MedSurg & Neurotech Growth Insights
Explore Stryker Corp’s Q2 2026 earnings reveal: MedSurg & Neurotechnology growth, orthopedic implant performance, and future strategy insights.
2 minutes to read
STRYKER CORP
Cyberattack Hits Stryker Corp, Disrupts Operations While Patient Services Remain Safe
Explore how an Iranian‑linked cyberattack on Stryker Corp disrupted its global operations, impacted supply chains, and what it means for investors and patient safety.
2 minutes to read
Institutional Buying Boosts Stryker Shares, Signals Strong Growth Outlook
Institutional trading shows mixed sentiment for Stryker Corp. while big investors like Penobscot add shares, confident in its R&D‑driven growth and global reach.
3 minutes to read
Institutional Surge and Analyst Upgrades Propel Stryker Shares to New Heights in 2026
Discover why institutional investors and analysts are bullish on Stryker Corp, the $135 billion medical‑device leader, after its Q4 2025 earnings beat and upgraded price targets.
3 minutes to read
Stryker Launches Next-Generation InThrill Thrombectomy System for Enhanced Medical Procedures
Stryker Corporation has launched its next-generation InThrill Thrombectomy System, a medical device designed to improve treatment of small vessel and arteriovenous thrombosis.
2 minutes to read
Stryker Corp Secures FDA Clearance for OptaBlate BVN System, Bolsters Market Position
Stryker Corp has secured FDA clearance for its OptaBlate BVN System, bolstering its market position and maintaining its strong valuation in the medical technology industry.
2 minutes to read